Exelixis (EXEL) Reports In-Line Q4 EPS, Slight Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Oppenheimer Upgrades Exelixis (EXEL) to Outperform
February 27, 2018 4:21 AM ESTOppenheimer upgraded Exelixis (NASDAQ: EXEL) from Perform to Outperform with a price target of $40.00.
Analyst Leah Rush Cann expects the company will continue to develop its commercial drugs Cabometyx & Cometriq as its partner Genetech continues to develop Cotellic. The analyst raises 2017-201 sales... More
